RET and thyroid gland carcinoma: Prior to the pandemic, the treatment and testing landscape for RET altered cancers was rapidly evolving—much of the data collection in this study co-occurred with the approval process of RET inhibitors for use in lung and thyroid cancer, potentially limiting the participants’ awareness of the importance of testing for RET alterations.